CDC Financial, Inc.

Position in INBX — Inhibrx Biosciences, Inc.

CIK 2077836 CHICAGO, IL

Back to INBX Full portfolio

Position in INBX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$13,277,317

+$4,905,166 QoQ

Shares Held

140,130

+12.5% QoQ

Ownership

0.952%

of shares outstanding

% of Portfolio

10.25%

of 13F equity value

Holder Rank

#21

of 161 holders

Holding Since

Dec 2025

3 quarters on record

Voting authority Sole 0% Shared 100% None 0%

Common Shares in INBX Over Time

Shares Held

Position Value (USD)

Derivatives in INBX

reported options exposure · as of Jun 30, 2026

CallValue

$2,842,500

CallShares

30,000

PutValue

PutShares

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Biotechnology

Healthcare · as of Jun 30, 2026

CDC Financial, Inc. holds $14,144,132 across 3 Biotechnology names. INBX ranks #1 (93.9% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	INBX	Inhibrx Biosciences, Inc. This page	140,130	$13,277,317
2	ZNTL	Zentalis Pharmaceuticals, Inc.	177,762	$862,145
3	CCCC	C4 Therapeutics, Inc.	1,000	$4,670

All Filings in INBX

Export CSV

5 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$2,842,500	30,000	-51.6%	Call	Defined	2026-08-14
2026-06-30	$13,277,317	140,130	+12.5%	Shares	Defined	2026-08-14
2026-03-31	$8,372,151	124,530	+12.4%	Shares	Defined	2026-05-15
2026-03-31	$4,168,260	62,000	—	Call	Defined	2026-05-15
2025-12-31	$8,753,990	110,810	—	Shares	Defined	2026-02-13
No filing history on record for this holder in this stock.